Evaluation of Treatments for Sore Throat Associated With Acute Pharyngitis and/or Viral Tonsillitis

The objective of this study is to conduct post-marketing clinical follow-up of four products: HMG, PHN, PHR, and TUR. This follow-up will consist of collecting clinical data in real-life conditions to confirm the tolerance, safety, and efficacy of medical devices used in the treatment of sore throats related to acute pharyngitis and/or viral-origin tonsillitis, while also assessing the benefit/risk ratio of the products.

Inclusion Criteria: * Pharyngitis or tonsillitis or acute nasopharyngitis or viral-origin sore throat with odynophagia that began less than 72 hours before the inclusion visit according to the investigator's judgment * Bacterial rhinopharyngitis with negative TROD test * Effective contraception for female patients of childbearing age * Cooperation and sufficient understanding to comply with the requirements of the trial * Acceptance of registration in the SI-RIPH database * Having received informed information and agreeing to give written consent * Affiliated with the French Social Security scheme. Exclusion Criteria: * Hypersensitivity/previous allergy to any of the product components, * Pharyngitis or tonsillitis or acute rhinopharyngitis complicated (phlegmon, acute otitis media, pneumonia…) or severely intolerable cough, * Positive antigen test for influenza A/B or COVID-19 and infection requiring etiological treatment according to the recommendations, * Other ongoing treatments for acute pharyngitis or tonsillitis (local treatment, antibiotics, corticosteroids, antiretroviral…), * Comorbidities or health conditions deemed incompatible with the trial by the investigator, * Recent otorhinolaryngology surgery (\